Overview on pharmacological and nutraceutical strategies for treatment of borderline dyslipidemia.
Cardiovascular system pathologies are responsible for 30-35% of deaths in industrialized countries thus making cardiovasculopathy the leading cause of disease-induced death. Many risk factors and the presence of a chronic inflammatory state represent the substrate for the development of cardiovascular disease. Hypercholesterolemia is considered one of the most important risk factors and consequently a primary therapeutic target. Numerous therapeutic strategies, mainly based on the use of statins, have been developed for hypercholesterolemia management. Unfortunately, those established drug therapies may present low effectiveness and low compliance by the patients. In this overview we discuss the results of a cohort observational prospectic clinical trial with active control which aims to evaluate the effectiveness of the experimental treatment with Omega Formula™ compared to conventional treatment with atorvastatin. The study was conducted in Italy on 30 subjects aged over 18 years enrolled according to defined criteria, divided into two homogeneous groups and treated for 3 consecutive months with 10 mg/die of atorvastatin (control group) or 3 tablets/die of Omega Formula™ (experimental group) and followed up with evaluation of biophysical and haematic parameters. The study highlights the expected result of reduction of total cholesterol plasmatic levels in the group of subjects treated with Omega Formula™ (-17.82%) and the effectiveness of the treatment with Omega Formula™ compared to treatment with atorvastatin in reducing hyperlipidemia.
General Practitioner Specialist in Internal Medicine Codogno, Lodi, Italy - lozziandrea@alice.it.
A
A
Lozzi
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D019587:Dietary Supplements; D005227:Fatty Acids / Q000008:administration & dosage*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000473:pathology / Q000628:therapy*; D007558:Italy; D008297:Male; D011758:Pyrroles / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D005227:Fatty Acids; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin